The German ADPKD Tolvaptan Treatment Registry

Launched by UNIVERSITY OF COLOGNE · Jul 9, 2015

Keywords

ClinConnect Summary

The German ADPKD Tolvaptan Treatment Registry is a study looking at how well a medication called tolvaptan works for people with a condition known as Autosomal Dominant Polycystic Kidney Disease (ADPKD). This trial aims to gather information from patients who are being considered for tolvaptan treatment, those who are planning to start it, or those who are already receiving it. By collecting real-world data, the study hopes to better understand how to manage treatment for ADPKD patients.

To participate in this trial, you need to be over 18 years old and have a confirmed diagnosis of ADPKD, which can be shown by a family history of the disease and kidney cysts. However, if you have severe kidney disease that requires dialysis or if you cannot provide informed consent, you won’t be eligible to join. If you take part, you can expect to share your experiences and treatment responses, contributing valuable information that may help improve care for others with this condition in the future.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Age \> 18 years
• • ADPKD proven by positive family history and evidence of renal cysts or diagnosed by treating physician
• • Presentation at our center for tolvaptan treatment indication, or tolvaptan treatment planned, or tolvaptan already started
• Exclusion Criteria:
• • Patients not capable of giving informed consent
• • End stage renal disease requiring renal replacement therapy
• • Patients receiving tolvaptan as "off-label use"